Table 1.
Group 1 (n = 91) Driver positive on tissue genotyping |
Group 2 (n = 19) Driver negative on tissue NGS | Group 3 (n=17) Driver unknown insufficient tissue | |||
---|---|---|---|---|---|
Detected in tumor | Tumor variant detected in plasma, N (sensitivity) | Detected in plasma, N (specificity) | Detected in plasma | ||
Driver | Total Subjects | 91 | 68 (75%) | 0 (100%) | 4 |
EGFR | 37 | 29 (78%) | 0 | 0 | |
KRAS | 29 | 23 (79%) | 0 | 4 | |
ALK | 8 | 5 (62%) | 0 | 0 | |
MET | 6 | 3 (50%) | 0 | 0 | |
ERBB2 | 4 | 4 (100%) | 0 | 0 | |
BRAF | 3 | 3 (100%) | 0 | 0 | |
ROS1 | 3 | 1 (33%) | 0 | 0 | |
RET | 1 | 0 (0%) | 0 | 0 | |
Resistance | EGFR | 13 | 11 (85%) | NA | NA |
MET | 2 | 0 (0%) | NA | NA |
NGS, next-generation sequencing.